5 Stocks Pushing The Health Services Industry Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 55 points (-0.4%) at 14,948 as of Wednesday, Aug. 21, 2013, 12:49 PM ET. The NYSE advances/declines ratio sits at 846 issues advancing vs. 2,101 declining with 78 unchanged.

The Health Services industry currently sits down 0.3% versus the S&P 500, which is down 0.4%. On the negative front, top decliners within the industry include Mindray Medical International ( MR), down 1.7%, Universal Health Services ( UHS), down 1.6%, Fresenius Medical Care AG & Co. KGaA ( FMS), down 1.2%, Smith & Nephew ( SNN), down 1.1% and St Jude Medical ( STJ), down 1.0%.

TheStreet would like to highlight 5 stocks pushing the industry lower today:

5. Cigna ( CI) is one of the companies pushing the Health Services industry lower today. As of noon trading, Cigna is down $0.80 (-1.0%) to $77.77 on light volume. Thus far, 430,814 shares of Cigna exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $77.42-$78.46 after having opened the day at $78.44 as compared to the previous trading day's close of $78.57.

Cigna Corporation, a health services organization, provides insurance and related products and services in the United States and internationally. Cigna has a market cap of $21.9 billion and is part of the health care sector. Shares are up 47.0% year to date as of the close of trading on Tuesday. Currently there are 8 analysts that rate Cigna a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Cigna as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Cigna Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

4. As of noon trading, HCA Holdings ( HCA) is down $0.28 (-0.7%) to $38.30 on light volume. Thus far, 1.3 million shares of HCA Holdings exchanged hands as compared to its average daily volume of 3.5 million shares. The stock has ranged in price between $38.17-$38.76 after having opened the day at $38.51 as compared to the previous trading day's close of $38.58.

HCA Holdings, Inc., through its subsidiaries, provides health care services in the United States. HCA Holdings has a market cap of $17.0 billion and is part of the health care sector. Shares are up 27.9% year to date as of the close of trading on Tuesday. Currently there are 13 analysts that rate HCA Holdings a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates HCA Holdings as a sell. The company's weaknesses can be seen in multiple areas, such as its weak operating cash flow and feeble growth in its earnings per share. Get the full HCA Holdings Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Covidien ( COV) is down $0.41 (-0.7%) to $60.55 on light volume. Thus far, 465,995 shares of Covidien exchanged hands as compared to its average daily volume of 2.7 million shares. The stock has ranged in price between $60.39-$61.00 after having opened the day at $60.86 as compared to the previous trading day's close of $60.96.

Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. Covidien has a market cap of $28.0 billion and is part of the health care sector. Shares are up 5.6% year to date as of the close of trading on Tuesday. Currently there are 13 analysts that rate Covidien a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Covidien as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, largely solid financial position with reasonable debt levels by most measures, notable return on equity and increase in stock price during the past year. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Covidien Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Express Scripts ( ESRX) is down $0.32 (-0.5%) to $64.32 on light volume. Thus far, 886,338 shares of Express Scripts exchanged hands as compared to its average daily volume of 4.2 million shares. The stock has ranged in price between $64.05-$64.58 after having opened the day at $64.24 as compared to the previous trading day's close of $64.64.

Express Scripts Holding Company provides a range of pharmacy benefit management (PBM) services primarily in the United States and Canada. It offers healthcare management and administration services on behalf of its clients. Express Scripts has a market cap of $52.7 billion and is part of the health care sector. Shares are up 19.0% year to date as of the close of trading on Tuesday. Currently there are 12 analysts that rate Express Scripts a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Express Scripts as a buy. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, growth in earnings per share, largely solid financial position with reasonable debt levels by most measures, increase in stock price during the past year and notable return on equity. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Express Scripts Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, UnitedHealth Group ( UNH) is down $0.59 (-0.8%) to $71.87 on light volume. Thus far, 1.3 million shares of UnitedHealth Group exchanged hands as compared to its average daily volume of 4.8 million shares. The stock has ranged in price between $71.57-$72.34 after having opened the day at $72.26 as compared to the previous trading day's close of $72.46.

UnitedHealth Group Incorporated operates as a diversified health and well-being company in the United States. UnitedHealth Group has a market cap of $72.9 billion and is part of the health care sector. Shares are up 33.6% year to date as of the close of trading on Tuesday. Currently there are 15 analysts that rate UnitedHealth Group a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates UnitedHealth Group as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, growth in earnings per share, attractive valuation levels and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full UnitedHealth Group Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 4 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).
null

If you liked this article you might like

Snap and Coca-Cola Are Among 16 Stocks That Are Ready to Change Direction

Snap and Coca-Cola Are Among 16 Stocks That Are Ready to Change Direction

The Really Big Money Rushes to Super Bowl

The Really Big Money Rushes to Super Bowl

Big Pharma and the Sellers of Its Products Now Have a Problem

Big Pharma and the Sellers of Its Products Now Have a Problem

Managed Care Stocks Thrashed on Amazon News but Could Be Buying Opportunity

Managed Care Stocks Thrashed on Amazon News but Could Be Buying Opportunity

Can Buffett and a Couple of Rich Celebrity CEOs Really Fix Healthcare?

Can Buffett and a Couple of Rich Celebrity CEOs Really Fix Healthcare?